Peter Clark, MA, MD, FRCP: A Payer Perspective

First International Summit on Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

May

Today In Oncology

Durvalumab After Chemoradiotherapy in Unresectable NSCLC Real-World Use and Outcomes

Dato-DXd in Advanced or Metastatic HR-Positive HER2-Negative or Triple-Negative Breast Cancer

United Kingdoms First Cardio-Oncology Service 10-Year Experience

Improving AML Outcomes Testing for MRD Prior to Bone Marrow Transplant

AI Model May Accurately Predict Mental Health Outcomes in Patients With Cancer

Peter Clark, MA, MD, FRCP: A Payer Perspective

Related Videos